references - shodhgangashodhganga.inflibnet.ac.in/bitstream/10603/2237/15/15_references.pdf · phd...
TRANSCRIPT
References
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 217
References
1. Abrahamyan LG, Mkrtchyan SR, Binley J, Lu M, Melikyan GB, Cohen FS: The
cytoplasmic tail slows the folding of human immunodeficiency virus type 1
Env from a late prebundle configuration into the six-helix bundle. J Virol 2005,
79(1):106-115.
2. Adams O, Schaal H, Scheid A: Natural variation in the amino acid sequence
around the HIV type 1 glycoprotein 160 cleavage site and its effect on
cleavability, subunit association, and membrane fusion. AIDS Res Hum
Retroviruses 2000, 16(13):1235-1245.
3. Agnihotri KD, Tripathy SP, Jere AP, Kale SM, Paranjape RS: Molecular analysis
of gp41 sequences of HIV type 1 subtype C from India. J Acquir Immune Defic
Syndr 2006, 41(3):345-351.
4. Agwale SM, Robbins KE, Odama L, Saekhou A, Zeh C, Edubio A, Njoku OM,
Sani-Gwarzo N, Gboun MF, Gao F et al: Development of an env gp41-based
heteroduplex mobility assay for rapid human immunodeficiency virus type 1
subtyping. J Clin Microbiol 2001, 39(6):2110-2114.
5. Amara RR, Robinson HL: A new generation of HIV vaccines. Trends Mol Med
2002, 8(10):489-495.
6. Amara RR, Smith JM, Staprans SI, Montefiori DC, Villinger F, Altman JD, O'Neil
SP, Kozyr NL, Xu Y, Wyatt LS et al: Critical role for Env as well as Gag-Pol in
control of a simian-human immunodeficiency virus 89.6P challenge by a DNA
prime/recombinant modified vaccinia virus Ankara vaccine. J Virol 2002,
76(12):6138-6146.
7. Ashkenazi A, Dixit VM: Death receptors: signaling and modulation. Science
1998, 281(5381):1305-1308.
8. Asjo B, Morfeldt-Manson L, Albert J, Biberfeld G, Karlsson A, Lidman K, Fenyo
EM: Replicative capacity of human immunodeficiency virus from patients
with varying severity of HIV infection. Lancet 1986, 2(8508):660-662.
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 218
9. Back NK, Smit L, De Jong JJ, Keulen W, Schutten M, Goudsmit J, Tersmette M:
An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop
affects virus neutralization. Virology 1994, 199(2):431-438.
10. Barnett SW, Rajasekar S, Legg H, Doe B, Fuller DH, Haynes JR, Walker CM,
Steimer KS: Vaccination with HIV-1 gp120 DNA induces immune responses
that are boosted by a recombinant gp120 protein subunit. Vaccine 1997,
15(8):869-873.
11. Barouch DH, Letvin NL: DNA vaccination for HIV-1 and SIV. Intervirology 2000,
43(4-6):282-287.
12. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M,
Craiu A, Zheng XX, Krivulka GR et al: Control of viremia and prevention of
clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.
Science 2000, 290(5491):486-492.
13. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J,
Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C et al: Isolation of a T-
lymphotropic retrovirus from a patient at risk for acquired immune deficiency
syndrome (AIDS). Science 1983, 220(4599):868-871.
14. Baskar PV, Ray SC, Rao R, Quinn TC, Hildreth JE, Bollinger RC: Presence in
India of HIV type 1 similar to North American strains. AIDS Res Hum
Retroviruses 1994, 10(8):1039-1041.
15. Batra M, Tien PC, Shafer RW, Contag CH, Katzenstein DA: HIV type 1 envelope
subtype C sequences from recent seroconverters in Zimbabwe. AIDS Res Hum
Retroviruses 2000, 16(10):973-979.
16. Beddows S, Schulke N, Kirschner M, Barnes K, Franti M, Michael E, Ketas T,
Sanders RW, Maddon PJ, Olson WC et al: Evaluating the immunogenicity of a
disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein
complex of human immunodeficiency virus type 1. J Virol 2005, 79(14):8812-
8827.
17. Belshe RB, Gorse GJ, Mulligan MJ, Evans TG, Keefer MC, Excler JL, Duliege AM,
Tartaglia J, Cox WI, McNamara J et al: Induction of immune responses to HIV-1
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 219
by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in
uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS 1998,
12(18):2407-2415.
18. Berger EA, Murphy PM, Farber JM: Chemokine receptors as HIV-1 coreceptors:
roles in viral entry, tropism, and disease. Annu Rev Immunol 1999, 17:657-700.
19. Berlioz-Torrent C, Shacklett BL, Erdtmann L, Delamarre L, Bouchaert I, Sonigo P,
Dokhelar MC, Benarous R: Interactions of the cytoplasmic domains of human
and simian retroviral transmembrane proteins with components of the clathrin
adaptor complexes modulate intracellular and cell surface expression of
envelope glycoproteins. J Virol 1999, 73(2):1350-1361.
20. Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, Wurm
FM, Hershberg RD, Cobb EK, Eichberg JW: Protection of chimpanzees from
infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but
not gp160. Nature 1990, 345(6276):622-625.
21. Bernstein HB, Tucker SP, Hunter E, Schutzbach JS, Compans RW: Human
immunodeficiency virus type 1 envelope glycoprotein is modified by O-linked
oligosaccharides. J Virol 1994, 68(1):463-468.
22. Binley J, Moore JP: HIV-cell fusion. The viral mousetrap. Nature 1997,
387(6631):346-348.
23. Binley JM, Wyatt R, Desjardins E, Kwong PD, Hendrickson W, Moore JP,
Sodroski J: Analysis of the interaction of antibodies with a conserved
enzymatically deglycosylated core of the HIV type 1 envelope glycoprotein
120. AIDS Res Hum Retroviruses 1998, 14(3):191-198.
24. Blot G, Janvier K, Le Panse S, Benarous R, Berlioz-Torrent C: Targeting of the
human immunodeficiency virus type 1 envelope to the trans-Golgi network
through binding to TIP47 is required for env incorporation into virions and
infectivity. J Virol 2003, 77(12):6931-6945.
25. Bolmstedt A, Hinkula J, Rowcliffe E, Biller M, Wahren B, Olofsson S: Enhanced
immunogenicity of a human immunodeficiency virus type 1 env DNA vaccine
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 220
by manipulating N-glycosylation signals. Effects of elimination of the V3
N306 glycan. Vaccine 2001, 20(3-4):397-405.
26. Bolmstedt A, Sjolander S, Hansen JE, Akerblom L, Hemming A, Hu SL, Morein
B, Olofsson S: Influence of N-linked glycans in V4-V5 region of human
immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-
neutralizing humoral response. J Acquir Immune Defic Syndr Hum Retrovirol 1996,
12(3):213-220.
27. Broder S, Gallo RC: A pathogenic retrovirus (HTLV-III) linked to AIDS. N Engl
J Med 1984, 311(20):1292-1297.
28. Bruce CB, Akrigg A, Sharpe SA, Hanke T, Wilkinson GW, Cranage MP:
Replication-deficient recombinant adenoviruses expressing the human
immunodeficiency virus Env antigen can induce both humoral and CTL
immune responses in mice. J Gen Virol 1999, 80 ( Pt 10):2621-2628.
29. Bruck C, Thiriart C, Fabry L, Francotte M, Pala P, Van Opstal O, Culp J,
Rosenberg M, De Wilde M, Heidt P et al: HIV-1 envelope-elicited neutralizing
antibody titres correlate with protection and virus load in chimpanzees.
Vaccine 1994, 12(12):1141-1148.
30. Burke B, Derby NR, Kraft Z, Saunders CJ, Dai C, Llewellyn N, Zharkikh I,
Vojtech L, Zhu T, Srivastava IK et al: Viral evolution in macaques coinfected
with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-
elicited anti-CCR5 SHIV neutralizing antibodies. Virology 2006, 355(2):138-151.
31. Burton DR, Barbas CF, 3rd: Human monoclonal antibodies: recent
achievements. Hosp Pract (Off Ed) 1994, 29(11):111, 114-116, 119 passim.
32. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, Nabel GJ,
Sodroski J, Wilson IA, Wyatt RT: HIV vaccine design and the neutralizing
antibody problem. Nat Immunol 2004, 5(3):233-236.
33. Burton DR, Montefiori DC: The antibody response in HIV-1 infection. AIDS
1997, 11 Suppl A:S87-98.
34. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, Sawyer LS,
Hendry RM, Dunlop N, Nara PL et al: Efficient neutralization of primary
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 221
isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994,
266(5187):1024-1027.
35. Cann AJ, Churcher MJ, Boyd M, O'Brien W, Zhao JQ, Zack J, Chen IS: The region
of the envelope gene of human immunodeficiency virus type 1 responsible for
determination of cell tropism. J Virol 1992, 66(1):305-309.
36. Cao J, Bergeron L, Helseth E, Thali M, Repke H, Sodroski J: Effects of amino acid
changes in the extracellular domain of the human immunodeficiency virus
type 1 gp41 envelope glycoprotein. J Virol 1993, 67(5):2747-2755.
37. Carrillo A, Ratner L: Human immunodeficiency virus type 1 tropism for T-
lymphoid cell lines: role of the V3 loop and C4 envelope determinants. J Virol
1996, 70(2):1301-1309.
38. Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, Tang A, Chen
M, Huang L, Harris V et al: Comparative immunogenicity in rhesus monkeys of
DNA plasmid, recombinant vaccinia virus, and replication-defective
adenovirus vectors expressing a human immunodeficiency virus type 1 gag
gene. J Virol 2003, 77(11):6305-6313.
39. Casimiro DR, Tang A, Perry HC, Long RS, Chen M, Heidecker GJ, Davies ME,
Freed DC, Persaud NV, Dubey S et al: Vaccine-induced immune responses in
rodents and nonhuman primates by use of a humanized human
immunodeficiency virus type 1 pol gene. J Virol 2002, 76(1):185-194.
40. Cecilia D, Kulkarni SS, Tripathy SP, Gangakhedkar RR, Paranjape RS, Gadkari
DA: Absence of coreceptor switch with disease progression in human
immunodeficiency virus infections in India. Virology 2000, 271(2):253-258.
41. Chackerian B, Rudensey LM, Overbaugh J: Specific N-linked and O-linked
glycosylation modifications in the envelope V1 domain of simian
immunodeficiency virus variants that evolve in the host alter recognition by
neutralizing antibodies. J Virol 1997, 71(10):7719-7727.
42. Chakrabarti BK, Kong WP, Wu BY, Yang ZY, Friborg J, Ling X, King SR,
Montefiori DC, Nabel GJ: Modifications of the human immunodeficiency virus
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 222
envelope glycoprotein enhance immunogenicity for genetic immunization. J
Virol 2002, 76(11):5357-5368.
43. Chakrabarti S, Panda S, Chatterjee A, Sarkar S, Manna B, Singh NB, Naik TN,
Detels R, Bhattacharya SK: HIV-1 subtypes in injecting drug users & their non-
injecting wives in Manipur, India. Indian J Med Res 2000, 111:189-194.
44. Chan DC, Fass D, Berger JM, Kim PS: Core structure of gp41 from the HIV
envelope glycoprotein. Cell 1997, 89(2):263-273.
45. Chan DC, Kim PS: HIV entry and its inhibition. Cell 1998, 93(5):681-684.
46. Chanda PK, Natuk RJ, Mason BB, Bhat BM, Greenberg L, Dheer SK, Molnar-
Kimber KL, Mizutani S, Lubeck MD, Davis AR et al: High level expression of the
envelope glycoproteins of the human immunodeficiency virus type I in
presence of rev gene using helper-independent adenovirus type 7
recombinants. Virology 1990, 175(2):535-547.
47. Cheng-Mayer C, Brown A, Harouse J, Luciw PA, Mayer AJ: Selection for
neutralization resistance of the simian/human immunodeficiency virus
SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular
envelope glycoprotein that modify N-linked glycosylation. J Virol 1999,
73(7):5294-5300.
48. Chhaya SU, Shankarkumar U: HLA antigen distribution in Jain population
from Mumbai, Maharashtra, India. Indian J Med Res 2001, 114:25-29.
49. Chohan B, Lang D, Sagar M, Korber B, Lavreys L, Richardson B, Overbaugh J:
Selection for human immunodeficiency virus type 1 envelope glycosylation
variants with shorter V1-V2 loop sequences occurs during transmission of
certain genetic subtypes and may impact viral RNA levels. J Virol 2005,
79(10):6528-6531.
50. Cleveland SM, McLain L, Cheung L, Jones TD, Hollier M, Dimmock NJ: A region
of the C-terminal tail of the gp41 envelope glycoprotein of human
immunodeficiency virus type 1 contains a neutralizing epitope: evidence for
its exposure on the surface of the virion. J Gen Virol 2003, 84(Pt 3):591-602.
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 223
51. Coffin J, Haase A, Levy JA, Montagnier L, Oroszlan S, Teich N, Temin H,
Toyoshima K, Varmus H, Vogt P et al: Human immunodeficiency viruses.
Science 1986, 232(4751):697.
52. Coffin J, Haase A, Levy JA, Montagnier L, Oroszlan S, Teich N, Temin H,
Toyoshima K, Varmus H, Vogt P et al: What to call the AIDS virus? Nature 1986,
321(6065):10.
53. Cole KS, Murphey-Corb M, Narayan O, Joag SV, Shaw GM, Montelaro RC:
Common themes of antibody maturation to simian immunodeficiency virus,
simian-human immunodeficiency virus, and human immunodeficiency virus
type 1 infections. J Virol 1998, 72(10):7852-7859.
54. Conley AJ, Kessler JA, 2nd, Boots LJ, Tung JS, Arnold BA, Keller PM, Shaw AR,
Emini EA: Neutralization of divergent human immunodeficiency virus type 1
variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal
antibody. Proc Natl Acad Sci U S A 1994, 91(8):3348-3352.
55. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR: Change in coreceptor
use coreceptor use correlates with disease progression in HIV-1--infected
individuals. J Exp Med 1997, 185(4):621-628.
56. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA:
The CD4 (T4) antigen is an essential component of the receptor for the AIDS
retrovirus. Nature 1984, 312(5996):763-767.
57. Dash B, McIntosh A, Barrett W, Daniels R: Deletion of a single N-linked
glycosylation site from the transmembrane envelope protein of human
immunodeficiency virus type 1 stops cleavage and transport of gp160
preventing env-mediated fusion. J Gen Virol 1994, 75 ( Pt 6):1389-1397.
58. Davis KC, Horsburgh CR, Jr., Hasiba U, Schocket AL, Kirkpatrick CH: Acquired
immunodeficiency syndrome in a patient with hemophilia. Ann Intern Med
1983, 98(3):284-286.
59. Dedera DA, Gu RL, Ratner L: Role of asparagine-linked glycosylation in
human immunodeficiency virus type 1 transmembrane envelope function.
Virology 1992, 187(1):377-382.
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 224
60. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P,
Marmon S, Sutton RE, Hill CM et al: Identification of a major co-receptor for
primary isolates of HIV-1. Nature 1996, 381(6584):661-666.
61. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, Denham SA,
Heil ML, Kasolo F, Musonda R, Hahn BH et al: Envelope-constrained
neutralization-sensitive HIV-1 after heterosexual transmission. Science 2004,
303(5666):2019-2022.
62. Dewar RL, Natarajan V, Vasudevachari MB, Salzman NP: Synthesis and
processing of human immunodeficiency virus type 1 envelope proteins
encoded by a recombinant human adenovirus. J Virol 1989, 63(1):129-136.
63. Doms RW, Moore JP: HIV-1 membrane fusion: targets of opportunity. J Cell Biol
2000, 151(2):F9-14.
64. Downing R, Pieniazek D, Hu DJ, Biryahwaho B, Fridlund C, Rayfield MA,
Sempala SD, Lal RB: Genetic characterization and phylogenetic analysis of
HIV-1 subtype C from Uganda. AIDS Res Hum Retroviruses 2000, 16(8):815-819.
65. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan
C, Maddon PJ, Koup RA, Moore JP et al: HIV-1 entry into CD4+ cells is
mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381(6584):667-673.
66. Dubay JW, Roberts SJ, Hahn BH, Hunter E: Truncation of the human
immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic
domain blocks virus infectivity. J Virol 1992, 66(11):6616-6625.
67. Earl PL, Broder CC, Long D, Lee SA, Peterson J, Chakrabarti S, Doms RW, Moss
B: Native oligomeric human immunodeficiency virus type 1 envelope
glycoprotein elicits diverse monoclonal antibody reactivities. J Virol 1994,
68(5):3015-3026.
68. Earl PL, Moss B, Doms RW: Folding, interaction with GRP78-BiP, assembly,
and transport of the human immunodeficiency virus type 1 envelope protein. J
Virol 1991, 65(4):2047-2055.
69. Edwards TG, Hoffman TL, Baribaud F, Wyss S, LaBranche CC, Romano J,
Adkinson J, Sharron M, Hoxie JA, Doms RW: Relationships between CD4
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 225
independence, neutralization sensitivity, and exposure of a CD4-induced
epitope in a human immunodeficiency virus type 1 envelope protein. J Virol
2001, 75(11):5230-5239.
70. Edwards TG, Wyss S, Reeves JD, Zolla-Pazner S, Hoxie JA, Doms RW, Baribaud
F: Truncation of the cytoplasmic domain induces exposure of conserved
regions in the ectodomain of human immunodeficiency virus type 1 envelope
protein. J Virol 2002, 76(6):2683-2691.
71. Farzan M, Choe H, Desjardins E, Sun Y, Kuhn J, Cao J, Archambault D,
Kolchinsky P, Koch M, Wyatt R et al: Stabilization of human immunodeficiency
virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into
the gp41 glycoprotein ectodomain. J Virol 1998, 72(9):7620-7625.
72. Fennie C, Lasky LA: Model for intracellular folding of the human
immunodeficiency virus type 1 gp120. J Virol 1989, 63(2):639-646.
73. Fenouillet E, Gluckman JC, Bahraoui E: Role of N-linked glycans of envelope
glycoproteins in infectivity of human immunodeficiency virus type 1. J Virol
1990, 64(6):2841-2848.
74. Fenouillet E, Jones I, Powell B, Schmitt D, Kieny MP, Gluckman JC: Functional
role of the glycan cluster of the human immunodeficiency virus type 1
transmembrane glycoprotein (gp41) ectodomain. J Virol 1993, 67(1):150-160.
75. Flanagan B, Pringle CR, Leppard KN: A recombinant human adenovirus
expressing the simian immunodeficiency virus Gag antigen can induce long-
lived immune responses in mice. J Gen Virol 1997, 78 ( Pt 5):991-997.
76. Freed EO, Martin MA: Virion incorporation of envelope glycoproteins with
long but not short cytoplasmic tails is blocked by specific, single amino acid
substitutions in the human immunodeficiency virus type 1 matrix. J Virol 1995,
69(3):1984-1989.
77. Freed EO, Martin MA: Domains of the human immunodeficiency virus type 1
matrix and gp41 cytoplasmic tail required for envelope incorporation into
virions. J Virol 1996, 70(1):341-351.
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 226
78. Furuta RA, Wild CT, Weng Y, Weiss CD: Capture of an early fusion-active
conformation of HIV-1 gp41. Nat Struct Biol 1998, 5(4):276-279.
79. Gabuzda DH, Lever A, Terwilliger E, Sodroski J: Effects of deletions in the
cytoplasmic domain on biological functions of human immunodeficiency
virus type 1 envelope glycoproteins. J Virol 1992, 66(6):3306-3315.
80. Gadkari DA, Moore D, Sheppard HW, Kulkarni SS, Mehendale SM, Bollinger
RC: Transmission of genetically diverse strains of HIV-1 in Pune, India. Indian
J Med Res 1998, 107:1-9.
81. Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, Palker
TJ, Redfield R, Oleske J, Safai B et al: Frequent detection and isolation of
cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for
AIDS. Science 1984, 224(4648):500-503.
82. Gallo SA, Finnegan CM, Viard M, Raviv Y, Dimitrov A, Rawat SS, Puri A, Durell
S, Blumenthal R: The HIV Env-mediated fusion reaction. Biochim Biophys Acta
2003, 1614(1):36-50.
83. Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, Cummins
LB, Arthur LO, Peeters M, Shaw GM et al: Origin of HIV-1 in the chimpanzee
Pan troglodytes troglodytes. Nature 1999, 397(6718):436-441.
84. Gao F, Morrison SG, Robertson DL, Thornton CL, Craig S, Karlsson G, Sodroski
J, Morgado M, Galvao-Castro B, von Briesen H et al: Molecular cloning and
analysis of functional envelope genes from human immunodeficiency virus
type 1 sequence subtypes A through G. The WHO and NIAID Networks for
HIV Isolation and Characterization. J Virol 1996, 70(3):1651-1667.
85. Gao F, Weaver EA, Lu Z, Li Y, Liao HX, Ma B, Alam SM, Scearce RM, Sutherland
LL, Yu JS et al: Antigenicity and immunogenicity of a synthetic human
immunodeficiency virus type 1 group m consensus envelope glycoprotein. J
Virol 2005, 79(2):1154-1163.
86. Garrity RR, Rimmelzwaan G, Minassian A, Tsai WP, Lin G, de Jong JJ, Goudsmit
J, Nara PL: Refocusing neutralizing antibody response by targeted dampening
of an immunodominant epitope. J Immunol 1997, 159(1):279-289.
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 227
87. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B,
Hahn BH, Bhattacharya T et al: Diversity considerations in HIV-1 vaccine
selection. Science 2002, 296(5577):2354-2360.
88. Girard M, Kieny MP, Pinter A, Barre-Sinoussi F, Nara P, Kolbe H, Kusumi K,
Chaput A, Reinhart T, Muchmore E et al: Immunization of chimpanzees confers
protection against challenge with human immunodeficiency virus. Proc Natl
Acad Sci U S A 1991, 88(2):542-546.
89. Gomez-Roman VR, Florese RH, Peng B, Montefiori DC, Kalyanaraman VS,
Venzon D, Srivastava I, Barnett SW, Robert-Guroff M: An adenovirus-based
HIV subtype B prime/boost vaccine regimen elicits antibodies mediating
broad antibody-dependent cellular cytotoxicity against non-subtype B HIV
strains. J Acquir Immune Defic Syndr 2006, 43(3):270-277.
90. Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA, Saxon A:
Pneumocystis carinii pneumonia and mucosal candidiasis in previously
healthy homosexual men: evidence of a new acquired cellular
immunodeficiency. N Engl J Med 1981, 305(24):1425-1431.
91. Graham FL, Prevec L: Methods for construction of adenovirus vectors. Mol
Biotechnol 1995, 3(3):207-220.
92. Gram GJ, Hemming A, Bolmstedt A, Jansson B, Olofsson S, Akerblom L, Nielsen
JO, Hansen JE: Identification of an N-linked glycan in the V1-loop of HIV-1
gp120 influencing neutralization by anti-V3 antibodies and soluble CD4. Arch
Virol 1994, 139(3-4):253-261.
93. Grundner C, Li Y, Louder M, Mascola J, Yang X, Sodroski J, Wyatt R: Analysis of
the neutralizing antibody response elicited in rabbits by repeated inoculation
with trimeric HIV-1 envelope glycoproteins. Virology 2005, 331(1):33-46.
94. Grundner C, Pancera M, Kang JM, Koch M, Sodroski J, Wyatt R: Factors limiting
the immunogenicity of HIV-1 gp120 envelope glycoproteins. Virology 2004,
330(1):233-248.
95. Haggerty S, Dempsey MP, Bukrinsky MI, Guo L, Stevenson M: Posttranslational
modifications within the HIV-1 envelope glycoprotein which restrict virus
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 228
assembly and CD4-dependent infection. AIDS Res Hum Retroviruses 1991,
7(6):501-510.
96. Hahn BH, Shaw GM, De Cock KM, Sharp PM: AIDS as a zoonosis: scientific
and public health implications. Science 2000, 287(5453):607-614.
97. Hallenberger S, Tucker SP, Owens RJ, Bernstein HB, Compans RW: Secretion of
a truncated form of the human immunodeficiency virus type 1 envelope
glycoprotein. Virology 1993, 193(1):510-514.
98. Hansen JE, Clausen H, Nielsen C, Teglbjaerg LS, Hansen LL, Nielsen CM,
Dabelsteen E, Mathiesen L, Hakomori SI, Nielsen JO: Inhibition of human
immunodeficiency virus (HIV) infection in vitro by anticarbohydrate
monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein
gp120 may be a target for virus neutralization. J Virol 1990, 64(6):2833-2840.
99. Hardy AM, Allen JR, Morgan WM, Curran JW: The incidence rate of acquired
immunodeficiency syndrome in selected populations. Jama 1985, 253(2):215-
220.
100. Hemsley A, Arnheim N, Toney MD, Cortopassi G, Galas DJ: A simple method
for site-directed mutagenesis using the polymerase chain reaction. Nucleic
Acids Res 1989, 17(16):6545-6551.
101. Hernandez LD, Hoffman LR, Wolfsberg TG, White JM: Virus-cell and cell-cell
fusion. Annu Rev Cell Dev Biol 1996, 12:627-661.
102. Hoffman TL, Doms RW: HIV-1 envelope determinants for cell tropism and
chemokine receptor use. Mol Membr Biol 1999, 16(1):57-65.
103. Jere A, Tripathy S, Agnihotri K, Jadhav S, Paranjape R: Genetic analysis of
Indian HIV-1 nef: subtyping, variability and implications. Microbes Infect 2004,
6(3):279-289.
104. Johnson WE, Desrosiers RC: Viral persistance: HIV's strategies of immune
system evasion. Annu Rev Med 2002, 53:499-518.
105. Johnson WE, Sauvron JM, Desrosiers RC: Conserved, N-linked carbohydrates
of human immunodeficiency virus type 1 gp41 are largely dispensable for
viral replication. J Virol 2001, 75(23):11426-11436.
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 229
106. Jones DH, McBride BW, Roff MA, Farrar GH: Efficient purification and
rigorous characterisation of a recombinant gp120 for HIV vaccine studies.
Vaccine 1995, 13(11):991-999.
107. Juillard V, Villefroy P, Godfrin D, Pavirani A, Venet A, Guillet JG: Long-term
humoral and cellular immunity induced by a single immunization with
replication-defective adenovirus recombinant vector. Eur J Immunol 1995,
25(12):3467-3473.
108. Kalpana A, Srikanth T, Abhay J, Sushama J, Swarali K, Ramesh P: gp120
sequences from HIV type 1 subtype C early seroconverters in India. AIDS Res
Hum Retroviruses 2004, 20(8):889-894.
109. Kent KA, Robinson J: Antigenic determinants on HIV-1 envelope
glycoproteins: a dickens of a time with oligomer twist. AIDS 1996, 10 Suppl
A:S107-114.
110. Koch M, Pancera M, Kwong PD, Kolchinsky P, Grundner C, Wang L,
Hendrickson WA, Sodroski J, Wyatt R: Structure-based, targeted
deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and
antibody recognition. Virology 2003, 313(2):387-400.
111. Kolchinsky P, Kiprilov E, Bartley P, Rubinstein R, Sodroski J: Loss of a single
N-linked glycan allows CD4-independent human immunodeficiency virus
type 1 infection by altering the position of the gp120 V1/V2 variable loops. J
Virol 2001, 75(7):3435-3443.
112. Korber B, Muldoon M, Theiler J, Gao F, Gupta R, Lapedes A, Hahn BH,
Wolinsky S, Bhattacharya T: Timing the ancestor of the HIV-1 pandemic
strains. Science 2000, 288(5472):1789-1796.
113. Kornfeld R, Kornfeld S: Assembly of asparagine-linked oligosaccharides.
Annu Rev Biochem 1985, 54:631-664.
114. Kowalski M, Potz J, Basiripour L, Dorfman T, Goh WC, Terwilliger E, Dayton
A, Rosen C, Haseltine W, Sodroski J: Functional regions of the envelope
glycoprotein of human immunodeficiency virus type 1. Science 1987,
237(4820):1351-1355.
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 230
115. Kumar S, Tamura K, Jakobsen IB, Nei M: MEGA2: molecular evolutionary
genetics analysis software. Bioinformatics 2001, 17(12):1244-1245.
116. Kunert R, Ruker F, Katinger H: Molecular characterization of five neutralizing
anti-HIV type 1 antibodies: identification of nonconventional D segments in
the human monoclonal antibodies 2G12 and 2F5. AIDS Res Hum Retroviruses
1998, 14(13):1115-1128.
117. Kurle S, Tripathy S, Jadhav S, Agnihotri K, Paranjape R: Full-length gag
sequences of HIV type 1 subtype C recent seroconverters from Pune, India.
AIDS Res Hum Retroviruses 2004, 20(10):1113-1118.
118. Kwong PD, Wyatt R, Majeed S, Robinson J, Sweet RW, Sodroski J, Hendrickson
WA: Structures of HIV-1 gp120 envelope glycoproteins from laboratory-
adapted and primary isolates. Structure 2000, 8(12):1329-1339.
119. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA:
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4
receptor and a neutralizing human antibody. Nature 1998, 393(6686):648-659.
120. LaBranche CC, Sauter MM, Haggarty BS, Vance PJ, Romano J, Hart TK,
Bugelski PJ, Marsh M, Hoxie JA: A single amino acid change in the cytoplasmic
domain of the simian immunodeficiency virus transmembrane molecule
increases envelope glycoprotein expression on infected cells. J Virol 1995,
69(9):5217-5227.
121. LaCasse RA, Follis KE, Trahey M, Scarborough JD, Littman DR, Nunberg JH:
Fusion-competent vaccines: broad neutralization of primary isolates of HIV.
Science 1999, 283(5400):357-362.
122. Lal RB, Chakrabarti S, Yang C: Impact of genetic diversity of HIV-1 on
diagnosis, antiretroviral therapy & vaccine development. Indian J Med Res 2005,
121(4):287-314.
123. Land A, Braakman I: Folding of the human immunodeficiency virus type 1
envelope glycoprotein in the endoplasmic reticulum. Biochimie 2001, 83(8):783-
790.
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 231
124. LaRosa GJ, Weinhold K, Profy AT, Langlois AJ, Dreesman GR, Boswell RN,
Shadduck P, Bolognesi DP, Matthews TJ, Emini EA et al: Conserved sequence
and structural elements in the HIV-1 principal neutralizing determinant:
further clarifications. Science 1991, 253(5024):1146.
125. Lasky LA, Nakamura G, Smith DH, Fennie C, Shimasaki C, Patzer E, Berman P,
Gregory T, Capon DJ: Delineation of a region of the human immunodeficiency
virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor.
Cell 1987, 50(6):975-985.
126. Learn GH, Muthui D, Brodie SJ, Zhu T, Diem K, Mullins JI, Corey L: Virus
population homogenization following acute human immunodeficiency virus
type 1 infection. J Virol 2002, 76(23):11953-11959.
127. Lee WR, Syu WJ, Du B, Matsuda M, Tan S, Wolf A, Essex M, Lee TH:
Nonrandom distribution of gp120 N-linked glycosylation sites important for
infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A
1992, 89(6):2213-2217.
128. Lee WR, Yu XF, Syu WJ, Essex M, Lee TH: Mutational analysis of conserved
N-linked glycosylation sites of human immunodeficiency virus type 1 gp41. J
Virol 1992, 66(3):1799-1803.
129. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, Gregory TJ:
Assignment of intrachain disulfide bonds and characterization of potential
glycosylation sites of the type 1 recombinant human immunodeficiency virus
envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol
Chem 1990, 265(18):10373-10382.
130. Levy JA, Shimabukuro J: Recovery of AIDS-associated retroviruses from
patients with AIDS or AIDS-related conditions and from clinically healthy
individuals. J Infect Dis 1985, 152(4):734-738.
131. Li B, Decker JM, Johnson RW, Bibollet-Ruche F, Wei X, Mulenga J, Allen S,
Hunter E, Hahn BH, Shaw GM et al: Evidence for potent autologous
neutralizing antibody titers and compact envelopes in early infection with
subtype C human immunodeficiency virus type 1. J Virol 2006, 80(11):5211-5218.
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 232
132. Li Y, Cleveland B, Klots I, Travis B, Richardson BA, Anderson D, Montefiori D,
Polacino P, Hu SL: Removal of a single N-linked glycan in human
immunodeficiency virus type 1 gp120 results in an enhanced ability to induce
neutralizing antibody responses. J Virol 2008, 82(2):638-651.
133. Li Y, Luo L, Rasool N, Kang CY: Glycosylation is necessary for the correct
folding of human immunodeficiency virus gp120 in CD4 binding. J Virol 1993,
67(1):584-588.
134. Lian Y, Srivastava I, Gomez-Roman VR, Zur Megede J, Sun Y, Kan E, Hilt S,
Engelbrecht S, Himathongkham S, Luciw PA et al: Evaluation of envelope
vaccines derived from the South African subtype C human immunodeficiency
virus type 1 TV1 strain. J Virol 2005, 79(21):13338-13349.
135. Liang X, Casimiro DR, Schleif WA, Wang F, Davies ME, Zhang ZQ, Fu TM,
Finnefrock AC, Handt L, Citron MP et al: Vectored Gag and Env but not Tat
show efficacy against simian-human immunodeficiency virus 89.6P challenge
in Mamu-A*01-negative rhesus monkeys. J Virol 2005, 79(19):12321-12331.
136. Liu MA: The immunologist's grail: vaccines that generate cellular immunity.
Proc Natl Acad Sci U S A 1997, 94(20):10496-10498.
137. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME,
Stuhlmann H, Koup RA, Landau NR: Homozygous defect in HIV-1 coreceptor
accounts for resistance of some multiply-exposed individuals to HIV-1
infection. Cell 1996, 86(3):367-377.
138. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG,
Ingersoll R, Sheppard HW, Ray SC: Full-length human immunodeficiency virus
type 1 genomes from subtype C-infected seroconverters in India, with
evidence of intersubtype recombination. J Virol 1999, 73(1):152-160.
139. Lu M, Kim PS: A trimeric structural subdomain of the HIV-1 transmembrane
glycoprotein. J Biomol Struct Dyn 1997, 15(3):465-471.
140. Lubeck MD, Natuk RJ, Chengalvala M, Chanda PK, Murthy KK, Murthy S,
Mizutani S, Lee SG, Wade MS, Bhat BM et al: Immunogenicity of recombinant
adenovirus-human immunodeficiency virus vaccines in chimpanzees
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 233
following intranasal administration. AIDS Res Hum Retroviruses 1994,
10(11):1443-1449.
141. Ly A, Stamatatos L: V2 loop glycosylation of the human immunodeficiency
virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and
CCR5 receptors and protects the virus from neutralization by anti-V3 loop and
anti-CD4 binding site antibodies. J Virol 2000, 74(15):6769-6776.
142. Maerz AL, Center RJ, Kemp BE, Kobe B, Poumbourios P: Functional
implications of the human T-lymphotropic virus type 1 transmembrane
glycoprotein helical hairpin structure. J Virol 2000, 74(14):6614-6621.
143. Maerz AL, Drummer HE, Wilson KA, Poumbourios P: Functional analysis of
the disulfide-bonded loop/chain reversal region of human immunodeficiency
virus type 1 gp41 reveals a critical role in gp120-gp41 association. J Virol 2001,
75(14):6635-6644.
144. Maitra A, Singh B, Banu S, Deshpande A, Robbins K, Kalish ML, Broor S, Seth
P: Subtypes of HIV type 1 circulating in India: partial envelope sequences.
AIDS Res Hum Retroviruses 1999, 15(10):941-944.
145. Malkevitch NV, Patterson LJ, Aldrich MK, Wu Y, Venzon D, Florese RH,
Kalyanaraman VS, Pal R, Lee EM, Zhao J et al: Durable protection of rhesus
macaques immunized with a replicating adenovirus-SIV multigene
prime/protein boost vaccine regimen against a second SIVmac251 rectal
challenge: role of SIV-specific CD8+ T cell responses. Virology 2006, 353(1):83-
98.
146. Mandal D, Jana S, Bhattacharya SK, Chakrabarti S: HIV type 1 subtypes
circulating in eastern and northeastern regions of India. AIDS Res Hum
Retroviruses 2002, 18(16):1219-1227.
147. Mascola JR, Sambor A, Beaudry K, Santra S, Welcher B, Louder MK, Vancott
TC, Huang Y, Chakrabarti BK, Kong WP et al: Neutralizing antibodies elicited
by immunization of monkeys with DNA plasmids and recombinant
adenoviral vectors expressing human immunodeficiency virus type 1 proteins.
J Virol 2005, 79(2):771-779.
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 234
148. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH,
Clements ML, Dolin R, Graham BS, Gorse GJ et al: Immunization with envelope
subunit vaccine products elicits neutralizing antibodies against laboratory-
adapted but not primary isolates of human immunodeficiency virus type 1.
The National Institute of Allergy and Infectious Diseases AIDS Vaccine
Evaluation Group. J Infect Dis 1996, 173(2):340-348.
149. McCaffrey RA, Saunders C, Hensel M, Stamatatos L: N-linked glycosylation of
the V3 loop and the immunologically silent face of gp120 protects human
immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and
anti-gp41 antibodies. J Virol 2004, 78(7):3279-3295.
150. McClure P, Curran R, Boneham S, Ball JK: A polymerase chain reaction
method for the amplification of full-length envelope genes of HIV-1 from
DNA samples containing single molecules of HIV-1 provirus. J Virol Methods
2000, 88(1):73-80.
151. McDougal JS, Nicholson JK, Cross GD, Cort SP, Kennedy MS, Mawle AC:
Binding of the human retrovirus HTLV-III/LAV/ARV/HIV to the CD4 (T4)
molecule: conformation dependence, epitope mapping, antibody inhibition,
and potential for idiotypic mimicry. J Immunol 1986, 137(9):2937-2944.
152. McMichael AJ, Hanke T: HIV vaccines 1983-2003. Nat Med 2003, 9(7):874-880.
153. Mehra NK, Jaini R, Rajalingam R, Balamurugan A, Kaur G: Molecular
diversity of HLA-A*02 in Asian Indians: predominance of A*0211. Tissue
Antigens 2001, 57(6):502-507.
154. Micoli KJ, Pan G, Wu Y, Williams JP, Cook WJ, McDonald JM: Requirement of
calmodulin binding by HIV-1 gp160 for enhanced FAS-mediated apoptosis. J
Biol Chem 2000, 275(2):1233-1240.
155. Montefiori DC, Pantaleo G, Fink LM, Zhou JT, Zhou JY, Bilska M, Miralles GD,
Fauci AS: Neutralizing and infection-enhancing antibody responses to human
immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis 1996,
173(1):60-67.
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 235
156. Moog C, Fleury HJ, Pellegrin I, Kirn A, Aubertin AM: Autologous and
heterologous neutralizing antibody responses following initial seroconversion
in human immunodeficiency virus type 1-infected individuals. J Virol 1997,
71(5):3734-3741.
157. Moore JP, Cao Y, Qing L, Sattentau QJ, Pyati J, Koduri R, Robinson J, Barbas
CF, 3rd, Burton DR, Ho DD: Primary isolates of human immunodeficiency
virus type 1 are relatively resistant to neutralization by monoclonal antibodies
to gp120, and their neutralization is not predicted by studies with monomeric
gp120. J Virol 1995, 69(1):101-109.
158. Moore JP, Ho DD: HIV-1 neutralization: the consequences of viral adaptation
to growth on transformed T cells. AIDS 1995, 9 Suppl A:S117-136.
159. Murakami T, Freed EO: The long cytoplasmic tail of gp41 is required in a cell
type-dependent manner for HIV-1 envelope glycoprotein incorporation into
virions. Proc Natl Acad Sci U S A 2000, 97(1):343-348.
160. Muster T, Guinea R, Trkola A, Purtscher M, Klima A, Steindl F, Palese P,
Katinger H: Cross-neutralizing activity against divergent human
immunodeficiency virus type 1 isolates induced by the gp41 sequence
ELDKWAS. J Virol 1994, 68(6):4031-4034.
161. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Ruker F,
Katinger H: A conserved neutralizing epitope on gp41 of human
immunodeficiency virus type 1. J Virol 1993, 67(11):6642-6647.
162. Nakayama EE, Shioda T, Tatsumi M, Xin X, Yu D, Ohgimoto S, Kato A, Sakai
Y, Ohnishi Y, Nagai Y: Importance of the N-glycan in the V3 loop of HIV-1
envelope protein for CXCR-4- but not CCR-5-dependent fusion. FEBS Lett 1998,
426(3):367-372.
163. Nara PL, Garrity RR, Goudsmit J: Neutralization of HIV-1: a paradox of
humoral proportions. Faseb J 1991, 5(10):2437-2455.
164. Natuk RJ, Chanda PK, Lubeck MD, Davis AR, Wilhelm J, Hjorth R, Wade MS,
Bhat BM, Mizutani S, Lee S et al: Adenovirus-human immunodeficiency virus
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 236
(HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing
antibodies in the dog model. Proc Natl Acad Sci U S A 1992, 89(16):7777-7781.
165. Natuk RJ, Lubeck MD, Chanda PK, Chengalvala M, Wade MS, Murthy SC,
Wilhelm J, Vernon SK, Dheer SK, Mizutani S et al: Immunogenicity of
recombinant human adenovirus-human immunodeficiency virus vaccines in
chimpanzees. AIDS Res Hum Retroviruses 1993, 9(5):395-404.
166. Novitsky V, Cao H, Rybak N, Gilbert P, McLane MF, Gaolekwe S, Peter T,
Thior I, Ndung'u T, Marlink R et al: Magnitude and frequency of cytotoxic T-
lymphocyte responses: identification of immunodominant regions of human
immunodeficiency virus type 1 subtype C. J Virol 2002, 76(20):10155-10168.
167. Novitsky V, Smith UR, Gilbert P, McLane MF, Chigwedere P, Williamson C,
Ndung'u T, Klein I, Chang SY, Peter T et al: Human immunodeficiency virus
type 1 subtype C molecular phylogeny: consensus sequence for an AIDS
vaccine design? J Virol 2002, 76(11):5435-5451.
168. Novitsky VA, Montano MA, McLane MF, Renjifo B, Vannberg F, Foley BT,
Ndung'u TP, Rahman M, Makhema MJ, Marlink R et al: Molecular cloning and
phylogenetic analysis of human immunodeficiency virus type 1 subtype C: a
set of 23 full-length clones from Botswana. J Virol 1999, 73(5):4427-4432.
169. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-Seisdedos
F, Schwartz O, Heard JM, Clark-Lewis I, Legler DF et al: The CXC chemokine
SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-
adapted HIV-1. Nature 1996, 382(6594):833-835.
170. Ogert RA, Lee MK, Ross W, Buckler-White A, Martin MA, Cho MW: N-linked
glycosylation sites adjacent to and within the V1/V2 and the V3 loops of
dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect
coreceptor usage and cellular tropism. J Virol 2001, 75(13):5998-6006.
171. Ohagen A, Devitt A, Kunstman KJ, Gorry PR, Rose PP, Korber B, Taylor J, Levy
R, Murphy RL, Wolinsky SM et al: Genetic and functional analysis of full-
length human immunodeficiency virus type 1 env genes derived from brain
and blood of patients with AIDS. J Virol 2003, 77(22):12336-12345.
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 237
172. Oldstone MB, Tishon A, Lewicki H, Dyson HJ, Feher VA, Assa-Munt N, Wright
PE: Mapping the anatomy of the immunodominant domain of the human
immunodeficiency virus gp41 transmembrane protein: peptide conformation
analysis using monoclonal antibodies and proton nuclear magnetic resonance
spectroscopy. J Virol 1991, 65(4):1727-1734.
173. Olshevsky U, Helseth E, Furman C, Li J, Haseltine W, Sodroski J: Identification
of individual human immunodeficiency virus type 1 gp120 amino acids
important for CD4 receptor binding. J Virol 1990, 64(12):5701-5707.
174. Ourmanov I, Brown CR, Moss B, Carroll M, Wyatt L, Pletneva L, Goldstein S,
Venzon D, Hirsch VM: Comparative efficacy of recombinant modified vaccinia
virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or
Env in macaques challenged with pathogenic SIV. J Virol 2000, 74(6):2740-2751.
175. Pan Z, Radding W, Zhou T, Hunter E, Mountz J, McDonald JM: Role of
calmodulin in HIV-potentiated Fas-mediated apoptosis. Am J Pathol 1996,
149(3):903-910.
176. Paranjape RS, Gadkari DA, Lubaki M, Quinn TC, Bollinger RC: Cross-reactive
HIV-1-specific CTL in recent seroconverters from Pune, India. Indian J Med Res
1998, 108:35-41.
177. Parker KC, Bednarek MA, Coligan JE: Scheme for ranking potential HLA-A2
binding peptides based on independent binding of individual peptide side-
chains. J Immunol 1994, 152(1):163-175.
178. Parren PW, Burton DR, Sattentau QJ: HIV-1 antibody--debris or virion? Nat
Med 1997, 3(4):366-367.
179. Parren PW, Gauduin MC, Koup RA, Poignard P, Fisicaro P, Burton DR,
Sattentau QJ: Relevance of the antibody response against human
immunodeficiency virus type 1 envelope to vaccine design. Immunol Lett 1997,
57(1-3):105-112.
180. Parren PW, Gauduin MC, Koup RA, Poignard P, Sattentau QJ, Fisicaro P,
Burton DR: Erratum to "Relevance of the antibody response against human
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 238
immunodeficiency virus type 1 envelope to vaccine design". Immunol Lett 1997,
58(2):125-132.
181. Parren PW, Moore JP, Burton DR, Sattentau QJ: The neutralizing antibody
response to HIV-1: viral evasion and escape from humoral immunity. Aids
1999, 13 Suppl A:S137-162.
182. Pastore C, Nedellec R, Ramos A, Pontow S, Ratner L, Mosier DE: Human
immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness
mutations compensate for V3 loss-of-fitness mutations. J Virol 2006, 80(2):750-
758.
183. Patterson LJ, Malkevitch N, Venzon D, Pinczewski J, Gomez-Roman VR, Wang
L, Kalyanaraman VS, Markham PD, Robey FA, Robert-Guroff M: Protection
against mucosal simian immunodeficiency virus SIV(mac251) challenge by
using replicating adenovirus-SIV multigene vaccine priming and subunit
boosting. J Virol 2004, 78(5):2212-2221.
184. Peng B, Wang LR, Gomez-Roman VR, Davis-Warren A, Montefiori DC,
Kalyanaraman VS, Venzon D, Zhao J, Kan E, Rowell TJ et al: Replicating rather
than nonreplicating adenovirus-human immunodeficiency virus recombinant
vaccines are better at eliciting potent cellular immunity and priming high-titer
antibodies. J Virol 2005, 79(16):10200-10209.
185. Perrin C, Fenouillet E, Jones IM: Role of gp41 glycosylation sites in the
biological activity of human immunodeficiency virus type 1 envelope
glycoprotein. Virology 1998, 242(2):338-345.
186. Piller SC, Dubay JW, Derdeyn CA, Hunter E: Mutational analysis of conserved
domains within the cytoplasmic tail of gp41 from human immunodeficiency
virus type 1: effects on glycoprotein incorporation and infectivity. J Virol 2000,
74(24):11717-11723.
187. Pinter A, Honnen WJ: O-linked glycosylation of retroviral envelope gene
products. J Virol 1988, 62(3):1016-1021.
188. Poon B, Hsu JF, Gudeman V, Chen IS, Grovit-Ferbas K: Formaldehyde-treated,
heat-inactivated virions with increased human immunodeficiency virus type 1
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 239
env can be used to induce high-titer neutralizing antibody responses. J Virol
2005, 79(16):10210-10217.
189. Poumbourios P, Wilson KA, Center RJ, El Ahmar W, Kemp BE: Human
immunodeficiency virus type 1 envelope glycoprotein oligomerization
requires the gp41 amphipathic alpha-helical/leucine zipper-like sequence. J
Virol 1997, 71(3):2041-2049.
190. Purtscher M, Trkola A, Grassauer A, Schulz PM, Klima A, Dopper S, Gruber G,
Buchacher A, Muster T, Katinger H: Restricted antigenic variability of the
epitope recognized by the neutralizing gp41 antibody 2F5. Aids 1996, 10(6):587-
593.
191. Quinones-Kochs MI, Buonocore L, Rose JK: Role of N-linked glycans in a
human immunodeficiency virus envelope glycoprotein: effects on protein
function and the neutralizing antibody response. J Virol 2002, 76(9):4199-4211.
192. Rao Z, Belyaev AS, Fry E, Roy P, Jones IM, Stuart DI: Crystal structure of SIV
matrix antigen and implications for virus assembly. Nature 1995, 378(6558):743-
747.
193. Reitter JN, Means RE, Desrosiers RC: A role for carbohydrates in immune
evasion in AIDS. Nat Med 1998, 4(6):679-684.
194. Rimsky LT, Shugars DC, Matthews TJ: Determinants of human
immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.
J Virol 1998, 72(2):986-993.
195. Ritola K, Pilcher CD, Fiscus SA, Hoffman NG, Nelson JA, Kitrinos KM, Hicks
CB, Eron JJ, Jr., Swanstrom R: Multiple V1/V2 env variants are frequently
present during primary infection with human immunodeficiency virus type 1.
J Virol 2004, 78(20):11208-11218.
196. Rizzuto C, Sodroski J: Fine definition of a conserved CCR5-binding region on
the human immunodeficiency virus type 1 glycoprotein 120. AIDS Res Hum
Retroviruses 2000, 16(8):741-749.
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 240
197. Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, Hendrickson
WA, Sodroski J: A conserved HIV gp120 glycoprotein structure involved in
chemokine receptor binding. Science 1998, 280(5371):1949-1953.
198. Rodenburg CM, Li Y, Trask SA, Chen Y, Decker J, Robertson DL, Kalish ML,
Shaw GM, Allen S, Hahn BH et al: Near full-length clones and reference
sequences for subtype C isolates of HIV type 1 from three different continents.
AIDS Res Hum Retroviruses 2001, 17(2):161-168.
199. Rose NF, Marx PA, Luckay A, Nixon DF, Moretto WJ, Donahoe SM, Montefiori
D, Roberts A, Buonocore L, Rose JK: An effective AIDS vaccine based on live
attenuated vesicular stomatitis virus recombinants. Cell 2001, 106(5):539-549.
200. Ross TM, Cullen BR: The ability of HIV type 1 to use CCR-3 as a coreceptor is
controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5
tropic V3 loop. Proc Natl Acad Sci U S A 1998, 95(13):7682-7686.
201. Rousso I, Mixon MB, Chen BK, Kim PS: Palmitoylation of the HIV-1 envelope
glycoprotein is critical for viral infectivity. Proc Natl Acad Sci U S A 2000,
97(25):13523-13525.
202. Rudd PM, Dwek RA: Glycosylation: heterogeneity and the 3D structure of
proteins. Crit Rev Biochem Mol Biol 1997, 32(1):1-100.
203. Saitou N, Nei M: The neighbor-joining method: a new method for
reconstructing phylogenetic trees. Mol Biol Evol 1987, 4(4):406-425.
204. Santra S, Seaman MS, Xu L, Barouch DH, Lord CI, Lifton MA, Gorgone DA,
Beaudry KR, Svehla K, Welcher B et al: Replication-defective adenovirus
serotype 5 vectors elicit durable cellular and humoral immune responses in
nonhuman primates. J Virol 2005, 79(10):6516-6522.
205. Sattentau QJ, Zolla-Pazner S, Poignard P: Epitope exposure on functional,
oligomeric HIV-1 gp41 molecules. Virology 1995, 206(1):713-717.
206. Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R,
Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR: The broadly
neutralizing anti-human immunodeficiency virus type 1 antibody 2G12
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 241
recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.
J Virol 2002, 76(14):7306-7321.
207. Schonning K, Jansson B, Olofsson S, Nielsen JO, Hansen JS: Resistance to V3-
directed neutralization caused by an N-linked oligosaccharide depends on the
quaternary structure of the HIV-1 envelope oligomer. Virology 1996, 218(1):134-
140.
208. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van
Steenwijk RP, Lange JM, Schattenkerk JK, Miedema F, Tersmette M: Biological
phenotype of human immunodeficiency virus type 1 clones at different stages
of infection: progression of disease is associated with a shift from
monocytotropic to T-cell-tropic virus population. J Virol 1992, 66(3):1354-1360.
209. Schuitemaker H, Kootstra NA, de Goede RE, de Wolf F, Miedema F, Tersmette
M: Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants
detectable in all stages of HIV-1 infection lack T-cell line tropism and
syncytium-inducing ability in primary T-cell culture. J Virol 1991, 65(1):356-363.
210. Schwartz S, Felber BK, Fenyo EM, Pavlakis GN: Rapidly and slowly
replicating human immunodeficiency virus type 1 isolates can be
distinguished according to target-cell tropism in T-cell and monocyte cell
lines. Proc Natl Acad Sci U S A 1989, 86(18):7200-7203.
211. Shankarappa R, Chatterjee R, Learn GH, Neogi D, Ding M, Roy P, Ghosh A,
Kingsley L, Harrison L, Mullins JI et al: Human immunodeficiency virus type 1
env sequences from Calcutta in eastern India: identification of features that
distinguish subtype C sequences in India from other subtype C sequences. J
Virol 2001, 75(21):10479-10487.
212. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, Farzadegan
H, Gupta P, Rinaldo CR, Learn GH, He X et al: Consistent viral evolutionary
changes associated with the progression of human immunodeficiency virus
type 1 infection. J Virol 1999, 73(12):10489-10502.
213. Shankarkumar U: HLA matching and problems related to cadaveric renal
transplantation in India. Indian J Med Sci 2001, 55(8):417-420.
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 242
214. Shankarkumar U, Ghosh K, Mohanty D: HLA B27 polymorphism in Western
India. Tissue Antigens 2002, 60(1):98-101.
215. Shioda T, Levy JA, Cheng-Mayer C: Macrophage and T cell-line tropisms of
HIV-1 are determined by specific regions of the envelope gp120 gene. Nature
1991, 349(6305):167-169.
216. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ,
Simon AJ, Trigona WL, Dubey SA et al: Replication-incompetent adenoviral
vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature
2002, 415(6869):331-335.
217. Spies CP, Ritter GD, Jr., Mulligan MJ, Compans RW: Truncation of the
cytoplasmic domain of the simian immunodeficiency virus envelope
glycoprotein alters the conformation of the external domain. J Virol 1994,
68(2):585-591.
218. Srinivas SK, Srinivas RV, Anantharamaiah GM, Compans RW, Segrest JP:
Cytosolic domain of the human immunodeficiency virus envelope
glycoproteins binds to calmodulin and inhibits calmodulin-regulated proteins.
J Biol Chem 1993, 268(30):22895-22899.
219. Staropoli I, Chanel C, Girard M, Altmeyer R: Processing, stability, and
receptor binding properties of oligomeric envelope glycoprotein from a
primary HIV-1 isolate. J Biol Chem 2000, 275(45):35137-35145.
220. Su J, Palm A, Wu Y, Sandin S, Hoglund S, Vahlne A: Deletion of the GPG
motif in the HIV type 1 V3 loop does not abrogate infection in all cells. AIDS
Res Hum Retroviruses 2000, 16(1):37-48.
221. Subramanian VS, Damodaran C: Distribution of HLA antigens in Sadhu
Chetty of Tamil Nadu, south India. Anthropol Anz 1995, 53(3):221-230.
222. Subramanian VS, Selvaraj P, Narayanan PR, Prabhakar R, Damodaran C:
Distribution of HLA (class I and class II) antigens in the native Dravidian
Hindus of Tamil Nadu, south India. Gene Geogr 1995, 9(1):15-24.
223. Tan K, Liu J, Wang J, Shen S, Lu M: Atomic structure of a thermostable
subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A 1997, 94(23):12303-12308.
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 243
224. Tencza SB, Mietzner TA, Montelaro RC: Calmodulin-binding function of LLP
segments from the HIV type 1 transmembrane protein is conserved among
natural sequence variants. AIDS Res Hum Retroviruses 1997, 13(3):263-269.
225. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG: The
CLUSTAL_X windows interface: flexible strategies for multiple sequence
alignment aided by quality analysis tools. Nucleic Acids Res 1997, 25(24):4876-
4882.
226. Tripathy S, Renjifo B, Wang WK, McLane MF, Bollinger R, Rodrigues J,
Osterman J, Tripathy S, Essex M: Envelope glycoprotein 120 sequences of
primary HIV type 1 isolates from Pune and New Delhi, India. AIDS Res Hum
Retroviruses 1996, 12(12):1199-1202.
227. Tripathy SP, Kulkarni SS, Jadhav SD, Agnihotri KD, Jere AJ, Kurle SN,
Bhattacharya SK, Singh K, Tripathy SP, Paranjape RS: Subtype B and subtype C
HIV type 1 recombinants in the northeastern state of Manipur, India. AIDS Res
Hum Retroviruses 2005, 21(2):152-157.
228. Trivedi VD, Cheng SF, Wu CW, Karthikeyan R, Chen CJ, Chang DK: The
LLSGIV stretch of the N-terminal region of HIV-1 gp41 is critical for binding
to a model peptide, T20. Protein Eng 2003, 16(4):311-317.
229. Uppal SS, Verma S, Dhot PS: Normal values of CD4 and CD8 lymphocyte
subsets in healthy indian adults and the effects of sex, age, ethnicity, and
smoking. Cytometry B Clin Cytom 2003, 52(1):32-36.
230. VanCott TC, Mascola JR, Loomis-Price LD, Sinangil F, Zitomersky N, McNeil J,
Robb ML, Birx DL, Barnett S: Cross-subtype neutralizing antibodies induced in
baboons by a subtype E gp120 immunogen based on an R5 primary human
immunodeficiency virus type 1 envelope. J Virol 1999, 73(6):4640-4650.
231. Vinner L, Wee EG, Patel S, Corbet S, Gao GP, Nielsen C, Wilson JM, Ertl HC,
Hanke T, Fomsgaard A: Immunogenicity in Mamu-A*01 rhesus macaques of a
CCR5-tropic human immunodeficiency virus type 1 envelope from the
primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus
5 boost. J Gen Virol 2003, 84(Pt 1):203-213.
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 244
232. Wang B, Spira TJ, Owen S, Lal RB, Saksena NK: HIV-1 strains from a cohort of
American subjects reveal the presence of a V2 region extension unique to slow
progressors and non-progressors. Aids 2000, 14(3):213-223.
233. Wang S, Arthos J, Lawrence JM, Van Ryk D, Mboudjeka I, Shen S, Chou TH,
Montefiori DC, Lu S: Enhanced immunogenicity of gp120 protein when
combined with recombinant DNA priming to generate antibodies that
neutralize the JR-FL primary isolate of human immunodeficiency virus type 1.
J Virol 2005, 79(12):7933-7937.
234. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF,
Salazar MG, Kilby JM, Saag MS et al: Antibody neutralization and escape by
HIV-1. Nature 2003, 422(6929):307-312.
235. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC: Atomic structure
of the ectodomain from HIV-1 gp41. Nature 1997, 387(6631):426-430.
236. Weissenhorn W, Wharton SA, Calder LJ, Earl PL, Moss B, Aliprandis E, Skehel
JJ, Wiley DC: The ectodomain of HIV-1 env subunit gp41 forms a soluble,
alpha-helical, rod-like oligomer in the absence of gp120 and the N-terminal
fusion peptide. EMBO J 1996, 15(7):1507-1514.
237. Willey RL, Rutledge RA, Dias S, Folks T, Theodore T, Buckler CE, Martin MA:
Identification of conserved and divergent domains within the envelope gene
of the acquired immunodeficiency syndrome retrovirus. Proc Natl Acad Sci U S
A 1986, 83(14):5038-5042.
238. Witvrouw M, Fikkert V, Hantson A, Pannecouque C, O'Keefe B R, McMahon J,
Stamatatos L, de Clercq E, Bolmstedt A: Resistance of human
immunodeficiency virus type 1 to the high-mannose binding agents
cyanovirin N and concanavalin A. J Virol 2005, 79(12):7777-7784.
239. Woods RJ, Edge CJ, Dwek RA: Protein surface oligosaccharides and protein
function. Nat Struct Biol 1994, 1(8):499-501.
240. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA,
Sodroski JG: The antigenic structure of the HIV gp120 envelope glycoprotein.
Nature 1998, 393(6686):705-711.
PhD Thesis (2008) Kalpana Agnihotri
National AIDS Research Institute, Pune Page 245
241. Wyatt R, Sodroski J: The HIV-1 envelope glycoproteins: fusogens, antigens,
and immunogens. Science 1998, 280(5371):1884-1888.
242. Wyma DJ, Kotov A, Aiken C: Evidence for a stable interaction of gp41 with
Pr55(Gag) in immature human immunodeficiency virus type 1 particles. J Virol
2000, 74(20):9381-9387.
243. Xiang ZQ, Yang Y, Wilson JM, Ertl HC: A replication-defective human
adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology
1996, 219(1):220-227.
244. Yang X, Farzan M, Wyatt R, Sodroski J: Characterization of stable, soluble
trimers containing complete ectodomains of human immunodeficiency virus
type 1 envelope glycoproteins. J Virol 2000, 74(12):5716-5725.
245. Ye L, Bu Z, Vzorov A, Taylor D, Compans RW, Yang C: Surface stability and
immunogenicity of the human immunodeficiency virus envelope
glycoprotein: role of the cytoplasmic domain. J Virol 2004, 78(24):13409-13419.
246. Zwart G, Back NK, Ramautarsing C, Valk M, van der Hoek L, Goudsmit J:
Frequent and early HIV-1MN neutralizing capacity in sera from Dutch HIV-1
seroconverters is related to antibody reactivity to peptides from the gp120 V3
domain. AIDS Res Hum Retroviruses 1994, 10(3):245-251.
247. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore
JP, Stiegler G, Katinger H, Burton DR et al: Broadly neutralizing antibodies
targeted to the membrane-proximal external region of human
immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001, 75(22):10892-
10905.